Aug 17, 2026 7:40 am EDT OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Aug 13, 2026 8:45 am EDT OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Jul 08, 2026 9:00 am EDT OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
Jun 26, 2026 7:40 am EDT OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
Jun 08, 2026 6:00 am EDT OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Jun 02, 2026 6:00 am EDT OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
May 29, 2026 7:20 am EDT OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World